Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $156.6 million for Q1 2026.

• Quarterly Total Current Liabilities rose 61.01% year-over-year to $156.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.6 million (up 61.01% YoY) and the FY2025 annual result came in at $139.2 million, up 38.33% from the prior year.
• Total Current Liabilities was $156.6 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $139.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $156.6 million in Q1 2026 and bottomed at $36.6 million in Q1 2023.
• A 5-year average of $81.1 million and a median of $64.2 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities declined 27.34% — and 2024, when it surged 79.46%.
• Kiniksa Pharmaceuticals International's Total Current Liabilities stood at $47.1 million in 2022, then surged by 35.27% to $63.7 million in 2023, then jumped by 58.05% to $100.6 million in 2024, then jumped by 38.33% to $139.2 million in 2025, then advanced by 12.52% to $156.6 million in 2026.
• Business Quant data shows KNSA's Total Current Liabilities at $156.6 million in Q1 2026, $139.2 million in Q4 2025, and $123.6 million in Q3 2025.